Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.
Recent announcements, achievements, and development milestones from PARI's pharmaceutical partners utilizing eFlow® Technology.
ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Trial of Novel Disease-Modifying Genetic Medicine, RCT1100 for the Treatment of Primary Ciliary Dyskinesia
Spexis reports solid safety and pharmacokinetics results from first-in-human study with inhaled murepavadin, a novel macrocycle compound
First Patient Enrolled in Phase 2 Clinical Study Evaluating ARINA-1 for the Treatment of NCFBE
Savara Awarded Promising Innovative Medicine (PIM) Designation in the United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Renovion Receives Notice of Study May Proceed Status for Lung Transplant Program